Premium
Aromatase inhibitor–induced hair loss in two adolescents
Author(s) -
Perper Marina,
Herskovitz Ingrid,
Tosti Antonella
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14339
Subject(s) - medicine , anastrozole , hair loss , aromatase inhibitor , endocrine system , adverse effect , aromatase , short stature , pediatrics , population , dermatology , endocrinology , breast cancer , cancer , hormone , environmental health
Hair loss and thinning are possible complications in those undergoing endocrine therapies with aromatase inhibitors. Alopecia in pediatric patients undergoing endocrine therapy has not been previously reported. We describe two adolescents, 14 and 16 years of age, who developed androgenetic alopecia following treatment with anastrozole for idiopathic short stature. Accordingly, the possible adverse event of alopecia should be considered in the pediatric population undergoing treatment with aromatase inhibitors.